Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis  Peter Willeit, Stephen Kaptoge,

Slides:



Advertisements
Similar presentations
Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Glycated Hemoglobin Measurement and Prediction of.
Advertisements

Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease: The PEACE Trial Torbjørn Omland, MD, PHD, MPH, Marc S.
Hazard ratio (& 95% CI) for 20 mmHg lower usual systolic BP
Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study  Dr Jack R W Brownrigg,
Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy
Volume 384, Issue 9961, Pages (December 2014)
Relation between Cardiovascular Disease Risk Markers and Brain Infarcts Detected by Magnetic Resonance Imaging in an Elderly Population  Ruta Nylander,
Copyright © 2014 American Medical Association. All rights reserved.
Volume 376, Issue 9750, Pages (October 2010)
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.
Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people  Dr Anoop Dinesh Shah, MRCP, Claudia Langenberg, PhD, Eleni.
Cardiac Troponin and its Relationship to Cardiovascular Outcomes in Community Populations – A Systematic Review and Meta-analysis  Julie Sze, MBBS, John.
Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis    The Lancet Diabetes &
Volume 388, Issue 10046, Pages (August 2016)
Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study  Dr Danish Saleheen, PhD,
Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment 
Associations of ambient coarse particulate matter, nitrogen dioxide, and carbon monoxide with the risk of kidney disease: a cohort study  Benjamin Bowe,
Volume 375, Issue 9709, Pages (January 2010)
Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis    The Lancet Diabetes &
Volume 376, Issue 9750, Pages (October 2010)
Volume 392, Issue 10145, Pages (August 2018)
Body-mass index and all-cause mortality – Authors' reply
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Blood Lead Levels and Decreased Kidney Function in a Population-Based Cohort  Florencia Harari, Gerd Sallsten, Anders Christensson, Marinka Petkovic, Bo.
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta- analysis of individual participant data from randomised trials 
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.
Blood Lead Levels and Decreased Kidney Function in a Population-Based Cohort  Florencia Harari, Gerd Sallsten, Anders Christensson, Marinka Petkovic, Bo.
Socioeconomic disparities in first stroke incidence, quality of care, and survival: a nationwide registry-based cohort study of 44 million adults in England 
Description of studies for pooled analyses
Body-mass index and all-cause mortality – Authors' reply
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies  Prospective Studies Collaboration  The.
Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3·6 million adults in the UK  Krishnan Bhaskaran, PhD,
Effect of diabetes duration and glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based prospective cohort study  William.
Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies 
Volume 352, Pages S15-S18 (October 1998)
Volume 379, Issue 9822, Pages (March 2012)
Mortality in single fathers compared with single mothers and partnered parents: a population-based cohort study  Maria Chiu, PhD, Farah Rahman, MPH, Simone.
Low-level lead exposure and mortality in US adults: a population-based cohort study  Prof Bruce P Lanphear, MD, Stephen Rauch, MPH, Peggy Auinger, MS,
OR (95% CI) for CHD associated with inflammatory markers in all participants and in subsets of non-users of statins or non-users of aspirin therapy. OR.
Volume 8, Issue 2, Pages (February 2011)
Volume 93, Issue 1, Pages (January 2018)
Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China  Iona Y Millwood, DPhil,
Volume 375, Issue 9725, Pages (May 2010)
Trajectories of cardiometabolic risk factors before diagnosis of three subtypes of type 2 diabetes: a post-hoc analysis of the longitudinal Whitehall.
Potassium levels and risk of in-hospital arrhythmias and mortality in patients admitted with suspected acute coronary syndrome  Jonas Faxén, Hong Xu,
Volume 389, Issue 10088, Pages (June 2017)
Volume 376, Issue 9750, Pages (October 2010)
Volume 393, Issue 10172, Pages (February 2019)
Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people  Dr Anoop Dinesh Shah, MRCP, Claudia Langenberg, PhD, Eleni.
Body-mass index, blood pressure, and cause-specific mortality in India: a prospective cohort study of 500 810 adults  Vendhan Gajalakshmi, PhD, Ben Lacey,
C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study  Heart Protection.
Anna J Dare, Calvin Ke, Wilson Suraweera, Peter Rodriguez, Prabhat Jha 
Volume 371, Issue 9628, Pages (June 2008)
Volume 379, Issue 9822, Pages (March 2012)
Muh Geot Wong, Vlado Perkovic  The Lancet Diabetes & Endocrinology 
Thank you to our diverse (but not diverse enough) reviewers
Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial  Dr David Preiss, PhD, Suzanne M Lloyd,
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Volume 383, Issue 9921, Pages (March 2014)
Incidence and prevalence of dementia associated with transient ischaemic attack and stroke: analysis of the population-based Oxford Vascular Study  Sarah.
Burden of hypertension and associated risks for cardiovascular mortality in Cuba: a prospective cohort study  Prof Nurys Armas Rojas, MBChB, Emily Dobell,
Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28.
Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross- sectional, genetically stratified survival analysis from UK Biobank 
Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm
Volume 75, Issue 1, Pages (January 2009)
Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimer's disease: A prospective study.
Risk differences for incident stroke, coronary heart disease (CHD), and cardiovascular mortality (per 1000 person-years) by clinical risk factor in the.
Volume 5, Issue 12, Pages (December 2018)
Trends in temperature-related age-specific and sex-specific mortality from cardiovascular diseases in Spain: a national time-series analysis  Hicham Achebak,
Presentation transcript:

Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis  Peter Willeit, Stephen Kaptoge, Paul Welsh, Adam S Butterworth, Rajiv Chowdhury, Sarah A Spackman, Lisa Pennells, Pei Gao, Stephen Burgess, Daniel F Freitag, Michael Sweeting, Angela M Wood, Nancy R Cook, Suzanne Judd, Stella Trompet, Vijay Nambi, Michael Hecht Olsen, Brendan M Everett, Frank Kee, Johan Ärnlöv, Veikko Salomaa, Daniel Levy, Jussi Kauhanen, Jari A Laukkanen, Maryam Kavousi, Toshiharu Ninomiya, Juan-Pablo Casas, Lori B Daniels, Lars Lind, Caroline N Kistorp, Jens Rosenberg, Thomas Mueller, Speranza Rubattu, Demosthenes B Panagiotakos, Oscar H Franco, James A de Lemos, Andreas Luchner, Jorge R Kizer, Stefan Kiechl, Jukka T Salonen, S Goya Wannamethee, Rudolf A de Boer, Børge G Nordestgaard, Jonas Andersson, Torben Jørgensen, Olle Melander, Christie M Ballantyne, Christopher DeFilippi, Paul M Ridker, Mary Cushman, Wayne D Rosamond, Simon G Thompson, Vilmundur Gudnason, Naveed Sattar, John Danesh, Emanuele Di Angelantonio Peter Willeit, Stephen Kaptoge, Paul Welsh, Adam S Butterworth, Rajiv Chowdhury, Sarah A Spackman, Lisa Pennells, Pei Gao, Stephen Burgess, Daniel F Freitag, Michael Sweeting, Angela M Wood, Nancy R Cook, Suzanne Judd, Stella Trompet, Vijay Nambi, Michael Hecht Olsen, Brendan M Everett, Frank Kee, Johan Ärnlöv, Veikko Salomaa, Daniel Levy, Jussi Kauhanen, Jari A Laukkanen, Maryam Kavousi, Toshiharu Ninomiya, Juan- Pablo Casas, Lori B Daniels, Lars Lind, Caroline N Kistorp, Jens Rosenberg, Thomas Mueller, Speranza Rubattu, Demosthenes B Panagiotakos, Oscar H Franco, James A de Lemos, Andreas Luchner, Jorge R Kizer, Stefan Kiechl, Jukka T Salonen, S Goya Wannamethee, Rudolf A de Boer, Børge G Nordestgaard, Jonas Andersson, Torben Jørgensen, Olle Melander, Christie M Ballantyne, Christopher DeFilippi, Paul M Ridker, Mary Cushman, Wayne D Rosamond, Simon G Thompson, Vilmundur Gudnason, Naveed Sattar, John Danesh, Emanuele Di Angelantonio  The Lancet Diabetes & Endocrinology  Volume 4, Issue 10, Pages 840-849 (October 2016) DOI: 10.1016/S2213-8587(16)30196-6 Copyright © 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions

Figure 1 Associations of NT-proBNP and HDL-C concentrations with first-onset coronary heart disease, stroke, and heart failure Risk ratios adjusted for age, smoking status, history of diabetes, systolic blood pressure, and total cholesterol and HDL-C concentration (HDL-C concentration only for NT-proBNP concentration analysis) and stratified by sex. Analyses involved 4716 coronary heart disease outcomes (from 34 cohorts), 3768 stroke outcomes (from 30 cohorts), and 2021 heart failure outcomes (from 16 cohorts). The size of the circles is proportional to the inverse of the variance of the respective estimate. Error bars are 95% CIs, estimated from floated variances. HDL-C=HDL cholesterol. NT-proBNP=N-terminal-pro-B-type natriuretic peptide. The Lancet Diabetes & Endocrinology 2016 4, 840-849DOI: (10.1016/S2213-8587(16)30196-6) Copyright © 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions

Figure 2 Associations of NT-proBNP and HDL-C concentrations with several incident first-onset cardiovascular outcomes Risk ratios adjusted for age, smoking status, history of diabetes, systolic blood pressure, and total cholesterol and HDL-C concentration (HDL-C concentration only for NT-proBNP concentration analysis) and stratified by sex. HDL-C=HDL cholesterol. NT-proBNP=N-terminal-pro-B-type natriuretic peptide. *Top versus bottom third of NT-proBNP concentration. †Bottom versus top third of HDL-C concentration. ‡Subsumes deaths due to cardiac arrhythmia, hypertensive disease, pulmonary embolism, complications and ill defined descriptions of heart disease, sudden death, aortic aneurysms, and peripheral vascular disease. The Lancet Diabetes & Endocrinology 2016 4, 840-849DOI: (10.1016/S2213-8587(16)30196-6) Copyright © 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions

Figure 3 Improvement in risk discrimination for first-onset individual and composite cardiovascular disease outcomes by addition of information about NT-proBNP concentration compared with that about HDL-C concentration Analyses involved 8323 outcomes for the combination of coronary heart disease plus stroke (from 32 cohorts), 6582 outcomes for the combination of coronary heart disease plus stroke plus heart failure (from 22 cohorts), 4552 coronary heart disease outcomes (from 32 cohorts), 3768 stroke outcomes (from 30 cohorts), and 2021 heart failure outcomes (from 16 cohorts). HDL-C=HDL cholesterol. NT-proBNP=N-terminal-pro-B-type natriuretic peptide. *The reference model included information about age, sex, smoking, systolic blood pressure, history of diabetes, and concentration of total cholesterol. The Lancet Diabetes & Endocrinology 2016 4, 840-849DOI: (10.1016/S2213-8587(16)30196-6) Copyright © 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions

Figure 4 Improvement in risk discrimination for first-onset individual and composite cardiovascular outcomes by addition of information about CRP and NT-proBNP concentration to a model with conventional risk factors Analyses involved 7618 outcomes for the combination of coronary heart disease plus stroke (from 28 cohorts), 5492 outcomes for the combination of coronary heart disease plus stroke plus heart failure (from 18 cohorts), 4120 coronary heart disease outcomes (from 27 cohorts), 3487 stroke outcomes (from 26 cohorts), and 1606 heart failure outcomes (from 13 cohorts). CRP=C-reactive protein. NT-proBNP=N-terminal-pro-B-type natriuretic peptide. *The reference model included information about age, sex, smoking, systolic blood pressure, history of diabetes, and concentrations of total and HDL cholesterol. The Lancet Diabetes & Endocrinology 2016 4, 840-849DOI: (10.1016/S2213-8587(16)30196-6) Copyright © 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions